Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 4/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 5/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.35 |
| ▸ | PEPD | P12955 | 1/20 | 0.34 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.34 |
| ▸ | FAP | Q12884 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29273284 | 1.00 | NR1H2 (0.37) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL25619373 | 1.00 | NR1H2 (0.37) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL29273287 | 1.00 | NR1H2 (0.37) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL25619371 | 1.00 | NR1H2 (0.37) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL31328756 | 0.90 | NR1H2 (0.35) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL18023576 | 0.85 | HTRA1 (0.34) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL19664090 | 0.85 | HTRA1 (0.34) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL19671511 | 0.85 | HTRA1 (0.34) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL4084639 | 0.83 | PIK3CD (0.45) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL4498311 | 0.83 | PIK3CD (0.45) | NR1H2CHRM2CHRM1CHRM3DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250101043-A1 | KRAS INHIBITORS | ELI LILLY AND COMPANY | 2025-03-27 | — | — | US | disclosed |
| WO-2025040767-A1 | 2-(3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL)-1,3,5-TRIAZINE DERIVATIVES AS KRAS G12D INHIBITORS FOR THE TREATMENT OF CANCER | SANOFI (FR) | 2025-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101043-A1 | KRAS INHIBITORS | KRAS, NRAS, HRAS | NR1H2 1327/4885CHRM2 4668/4885CHRM1 4532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.